News – Page 1118 – Endpoints News

Tesaro gets its PD-1 registration study started, hunting accelerated OK; Ultragenyx hustles into PhIII

9 years ago

Pfizer wins a “breakthrough” title for ALK/ROS1 contender lorlatinib after hustling into PhIII

9 years ago

Roche silently whisks away its lead $1.7B Seragon drug in a Q1 footnote

9 years ago

Neil Kumar's BridgeBio lines up subsidiary No. 9 with a $27M shot at TTR amyloidosis

9 years ago

An ailing AstraZeneca kicks two drugs out of the pipeline and an ex-drug partner’s share price is blasted

9 years ago

The top 9 overseas accounts in biopharma hold $133B in M&A firepower

9 years ago

Scangos left Biogen in style, taking a final $17.7M compensation package for one last, disappointing year

9 years ago

Stymied on Nasdaq, Apple Tree’s Braeburn sinks another short putt with late-stage implant

9 years ago

Analysts offer a lukewarm endorsement to Amgen for PhIII migraine data; Arsanis raises $45.5M Series D; Covance faces ...

9 years ago

Buzz: Teva Chairman Sol Barer is getting busy with a top-to-bottom rehab plan for a wounded giant

9 years ago

Way over budget and years late — AstraZeneca’s massive HQ project offers a troubling symbol

9 years ago

Medicines Co., Alnylam prepare to throw the dice on a late-stage effort to leapfrog PCSK9 giants

9 years ago

Gottlieb tackles speculators, FDA transparency and the R&D gold standard in a last round of queries ahead of ...

9 years ago

Otsuka gobbles up more global rights for Akebia’s vadadustat, chipping in to a pot now worth $2B-plus

9 years ago

Regeneron’s CEO, CSO saw their compensation slashed in ’16 — but it’s still a jaw-dropping sum

9 years ago

Dear Alexion: Geoff Meacham has some tough love to offer as you plan the rest of your year

9 years ago

Merck KGaA sells off its biosimilars portfolio in €670M deal; uniQure boosted by PRIME; Struggling Ophthotech gets ...

9 years ago

Novartis takes a $200M hit to write off a flop as execs spell out a cautious R&D strategy

9 years ago

Blitzed by trial failures, OncoMed axes half its staff and retrenches around PhI drugs

9 years ago

With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact

9 years ago

Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen

9 years ago

Marathon Pharmaceuticals signals it will wind down after stirring a hornet’s nest with $89,000 Duchenne treatment

9 years ago

Argenx files for a $75M IPO; PDUFA date looming, BioMarin wins CHMP nod for Brineura

9 years ago

Best in class? Eli Lilly claims a lead role awaits its CDK 4/6 drug abemaciclib after PhIII success

9 years ago

First page Previous page 1115 1116 111711181119 1120 1121 Next page Last page